These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 29344876)

  • 21. The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence.
    Feagan BG; Marabani M; Wu JJ; Faccin F; Spronk C; Castañeda-Hernández G
    Adv Ther; 2020 Nov; 37(11):4491-4518. PubMed ID: 32910420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
    Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
    JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review.
    Hillhouse E; Mathurin K; Bibeau J; Parison D; Rahal Y; Lachaine J; Beauchemin C
    Adv Ther; 2022 Jan; 39(1):455-487. PubMed ID: 34780028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.
    García-Beloso N; Altabás-González I; Samartín-Ucha M; Gayoso-Rey M; De Castro-Parga ML; Salgado-Barreira Á; Cibeira-Badia A; Piñeiro-Corrales MG; González-Vilas D; Pego-Reigosa JM; Martínez-López de Castro N
    Br J Clin Pharmacol; 2022 Feb; 88(4):1529-1550. PubMed ID: 34622969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review.
    Meijboom RW; Gardarsdottir H; Egberts TCG; Giezen TJ
    BioDrugs; 2022 Jan; 36(1):27-39. PubMed ID: 34870802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are we ready to close the discussion on the interchangeability of biosimilars?
    Ebbers HC; Schellekens H
    Drug Discov Today; 2019 Oct; 24(10):1963-1967. PubMed ID: 31254488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.
    Bloomfield D; D'Andrea E; Nagar S; Kesselheim A
    JAMA Oncol; 2022 Apr; 8(4):537-545. PubMed ID: 35113135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Biosimilar, so it looks alike, but what does it mean?" A qualitative study of Danish patients' perceptions of biosimilars.
    Varma M; Almarsdóttir AB; Druedahl LC
    Basic Clin Pharmacol Toxicol; 2022 May; 130(5):581-591. PubMed ID: 35261174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching.
    Declerck P; Bakalos G; Zintzaras E; Barton B; Schreitmüller T
    Clin Ther; 2018 May; 40(5):798-809.e2. PubMed ID: 29699853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.
    Huoponen S; Eberl A; Räsänen P; Roine RP; Sipponen T; Arkkila P; Blom M
    Medicine (Baltimore); 2020 Jan; 99(2):e18723. PubMed ID: 31914087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):373-389. PubMed ID: 31161461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review.
    Gisbert JP; Chaparro M
    Gastroenterol Hepatol; 2018; 41(6):389-405. PubMed ID: 29753532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
    Alvarez DF; Wolbink G; Cronenberger C; Orazem J; Kay J
    BioDrugs; 2020 Dec; 34(6):723-732. PubMed ID: 32990892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.